Eucheuma blood fat reducing tetrapeptide and application thereof

A technology of Eucheuma and blood lipid lowering, applied in the direction of application, tetrapeptide components, peptides, etc., to achieve good lipid-lowering activity, good blood-lipid-lowering activity, and the effect of reducing fat accumulation

Active Publication Date: 2019-03-01
清枫链食苏打饮品(吉林)有限公司
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, using Eucheuma as raw material, the process research on the preparation of Eucheuma hypolipidemic oligopeptides by enzymatic hydrolysis technology is in a blank stage

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Eucheuma blood fat reducing tetrapeptide and application thereof
  • Eucheuma blood fat reducing tetrapeptide and application thereof
  • Eucheuma blood fat reducing tetrapeptide and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] A blood lipid-lowering tetrapeptide of Eucheuma, the amino acid sequence of which is Phe-Tyr-Lys-Ala (FYKA), the molecular weight determined by ESI-MS is 527.50Da, and has good lipid-lowering activity. The Eucheuma hypolipidemic oligopeptide Phe-Tyr-Lys-Ala (FYKA) Eucheuma tetrapeptide Phe-Tyr-Lys-Ala (FYKA) can significantly reduce the amount of fat accumulation in liver cells induced by oleic acid, significantly reduce the The levels of triglyceride (TG) and total cholesterol (TC) indicated that Phe-Tyr-Lys-Ala (FYKA) had better lipid-lowering activity. Therefore, Phe-Tyr-Lys-Ala (FYKA) has good blood lipid-lowering activity and can be used in the development of blood-lipid-lowering related medicines, health care products, and special medical foods.

[0032] A preparation method of Eucheuma hypolipidemic tetrapeptide, comprising the preparation of Eucheuma algae protein, the enzymatic hydrolysis of Eucheuma algae protein, and the preparation of Eucheuma anti-oxidation...

Embodiment 2

[0044] A blood lipid-lowering tetrapeptide of Eucheuma, the amino acid sequence of which is Phe-Tyr-Lys-Ala (FYKA), the molecular weight determined by ESI-MS is 527.50Da, and has good lipid-lowering activity.

[0045] A preparation method of Eucheuma hypolipidemic tetrapeptide, comprising the preparation of Eucheuma algae protein, the enzymatic hydrolysis of Eucheuma algae protein, and the preparation of Eucheuma anti-oxidation oligopeptide, wherein the extraction solvent of the Eucheuma algae protein preparation step has a concentration of 0.1% (W / V) CaCl 2 solution, CaCl 2 The solution contains CaCl 2 2.5% ethacridine lactate and 15.0% potassium nitrate by weight.

[0046] The specific steps of the preparation method of the above-mentioned Eucheuma hypolipidemic tetrapeptide are:

[0047] 1) Preparation of Eucheuma algae protein: Take Eucheuma powder, add extraction solvent according to the ratio of material to liquid 1g:100mL and soak for 8h, then use ultrasonic frequenc...

Embodiment 3

[0054] A blood lipid-lowering tetrapeptide of Eucheuma, the amino acid sequence of which is Phe-Tyr-Lys-Ala (FYKA), the molecular weight determined by ESI-MS is 527.50Da, and has good lipid-lowering activity.

[0055]A preparation method of Eucheuma hypolipidemic tetrapeptide, comprising the preparation of Eucheuma algae protein, the enzymatic hydrolysis of Eucheuma algae protein, and the preparation of Eucheuma anti-oxidation oligopeptide, wherein the extraction solvent of the Eucheuma algae protein preparation step has a concentration of 0.5% (W / V) CaCl 2 solution, CaCl 2 The solution contains CaCl 2 3.0% ethacridine lactate and 16.0% potassium nitrate by weight.

[0056] The specific steps of the preparation method of the above-mentioned Eucheuma hypolipidemic tetrapeptide are:

[0057] 1) Preparation of Eucheuma algae protein: Take Eucheuma powder, add extraction solvent according to the ratio of material to liquid 1g:100mL and soak for 12 hours, then use ultrasonic fre...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a eucheuma blood fat reducing tetrapeptide and an application thereof, and belongs to the technical field of blood pressure reducing oligopeptide. The amino acid sequence of theeucheuma blood fat reducing tetrapeptide is Phe-Tyr-Lys-Ala (FYKA), and the eucheuma blood fat reducing tetrapeptide has good fat reducing activity. The eucheuma blood fat reducing tetrapeptide can be applied to preparation of blood fat reducing drugs, health care products and food additives. The eucheuma blood fat reducing tetrapeptide can remarkably reduce fat accumulation amount of oleic acidinduced hepatic cells, remarkably reduces the level of triglyceride (TG) and total cholesterol (TC) in the hepatic cells, has good blood fat reducing activity and can be used for developing the bloodfat reducing related drugs, the health care products and special medical food.

Description

technical field [0001] The invention belongs to the technical field of blood lipid-lowering oligopeptides, and in particular relates to a blood fat-lowering tetrapeptide of Eucheuma japonicus and its application. Background technique [0002] Abnormal fat metabolism or operation makes one or more lipids in plasma higher than normal value, which is called hyperlipidemia. At present, in China, hyperlipidemia is generally diagnosed as adult fasting serum total cholesterol exceeding 5.72 mmol / L and triglyceride exceeding 1.70 mmol / L. Those whose total cholesterol is between 5.2 and 5.7 mmol / L are called marginally elevated. Hyperlipidemia can be divided into two types: primary and secondary. Primary is related to congenital and heredity, most of which are caused by abnormality of receptors, enzymes or apolipoproteins involved in lipoprotein transport and metabolism due to single or multiple gene defects, or due to environmental factors (diet, nutrition, drugs) ). Secondary m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K5/107C07K1/36C07K1/34C07K1/20C07K1/16C12P21/06A61K38/07A61P3/06A23L33/18
CPCA23V2002/00A61K38/00A23L33/18A61P3/06C07K5/1016C12P21/06A23V2200/326A23V2250/55
Inventor 王斌李雪荣孙坤来
Owner 清枫链食苏打饮品(吉林)有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap